Literature DB >> 8682086

Interferon and thymic hormones in the therapy of human myocarditis and idiopathic dilated cardiomyopathy.

M Mirić1, A Misković, J D Vasiljević, N Keserović, M Pesić.   

Abstract

It is becoming increasingly apparent that idiopathic dilated cardiomyopathy (IDC) probably results from an acute viral myocarditis. One reasonable hypothesis is that persistent viral infection causes myocardial destruction leading to left ventricular dilatation and heart failure. The aim of this study was to evaluate the efficacy of interferon-alpha (IFN) and thymomodulin in the treatment of idiopathic myocarditis and IDC. Clinical, immunological, haemodynamic and histological evaluation was performed in 40 patients before inclusion in the study. Patients were randomized into three treatment groups: (a) conventional therapy plus IFN, (b) conventional therapy plus thymomodulin and (c) conventional therapy alone. Two-year follow-up included repeated endomyocardial biopsy, echocardiographic evaluation, treadmill exercise test, Holter monitoring study and radionuclide assessment of left ventricular function during exercise. Left ventricular ejection fraction increased during follow-up in most of the IFN-and thymomodulin-treated patients, and only in a few of conventionally treated patients. Left ventricular reserve was significantly higher at 2-year follow-up in patients treated with immunomodulators. No serious adverse effects were noticed during treatment. Our results suggest that treatment of myocarditis and/or IDC with IFN or thymomodulin induces an earlier and significantly superior clinical improvement than conventional therapy alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8682086     DOI: 10.1093/eurheartj/16.suppl_o.150

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

Review 1.  [Therapy of dilated cardiomyopathies with and without inflammation].

Authors:  G Hufnagel; S Pankuweit; B Maisch
Journal:  Med Klin (Munich)       Date:  1998-04-15

2.  Spontaneous activation of a MAVS-dependent antiviral signaling pathway determines high basal interferon-β expression in cardiac myocytes.

Authors:  Efraín E Rivera-Serrano; Nicole DeAngelis; Barbara Sherry
Journal:  J Mol Cell Cardiol       Date:  2017-08-16       Impact factor: 5.000

Review 3.  Herbal medicines for viral myocarditis.

Authors:  Zhao Lan Liu; Zhi Jun Liu; Jian Ping Liu; Min Yang; Joey Kwong
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

4.  Interferon regulatory factor 3 is required for viral induction of beta interferon in primary cardiac myocyte cultures.

Authors:  D L Noah; M A Blum; B Sherry
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response.

Authors:  Michael J Stewart; Kathleen Smoak; Mary Ann Blum; Barbara Sherry
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 6.  Herbal medicines for viral myocarditis.

Authors:  J P Liu; M Yang; X M Du
Journal:  Cochrane Database Syst Rev       Date:  2004

7.  Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity.

Authors:  Albert Heim; Sabine Weiss
Journal:  Med Microbiol Immunol       Date:  2003-09-12       Impact factor: 3.402

8.  Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses.

Authors:  Jennifer Zurney; Kristina E Howard; Barbara Sherry
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 9.  Immunosuppressive therapy in acute myocarditis: an 18 year systematic review.

Authors:  C P P Hia; W C L Yip; B C Tai; S C Quek
Journal:  Arch Dis Child       Date:  2004-06       Impact factor: 3.791

Review 10.  Viral myocarditis: diagnosis, aetiology and management.

Authors:  Uwe Kühl; Heinz-Peter Schultheiss
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.